Form 4: ProMIS Neurosciences Director Acquires Options in Recent Transaction
SEC Form 4 Filing
Director Patrick D. Kirwin acquired options to purchase 40,000 common shares of ProMIS Neurosciences Inc. at an exercise price of $1.11, according to a recent SEC filing.
Summary
- On October 3, 2024, Patrick D. Kirwin, a director of ProMIS Neurosciences Inc., acquired options to purchase 40,000 common shares.
- The exercise price for these options is $1.11 per share.
- 33% of the options vested immediately on October 3, 2024, with the remaining balance vesting ratably over the next 24 months, contingent upon continued service.
- The options expire on October 3, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative performance for the company.
Industry Context
This filing reflects standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of the options transaction and initial vesting of 33% of the options. |
| 10/03/2034 | Expiration date of the options. |
| 10/07/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.